Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843347 | 1.00 | CTSS (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL7060009 | 1.00 | CTSS (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL17828220 | 0.90 | CTSL (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL25251533 | 0.88 | CTSK (0.45) | CTSSCTSLCTSBCTSKTSHR | |
| SCHEMBL20899762 | 0.88 | CTSK (0.45) | CTSSCTSLCTSBCTSKTSHR | |
| SCHEMBL25225741 | 0.88 | CTSK (0.45) | CTSSCTSLCTSBCTSKTSHR | |
| SCHEMBL25219443 | 0.87 | PIN1 (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL4023206 | 0.87 | PIN1 (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL4023208 | 0.87 | PIN1 (0.50) | CTSSCTSLCTSBCTSDCTSK | |
| SCHEMBL25268690 | 0.86 | CALCRL (0.44) | CTSSCTSLCTSBCTSKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059213-A1 | LONP1 INHIBITORS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250059214-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4444727-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444726-A1 | LONP1 INHIBITORS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107470-A1 | LONP1 INHIBITORS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107481-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-108117582-A | Big ring epoxy ketone peptides and preparation method thereof and medical usage | 浙江大学 | 2018-06-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059213-A1 | LONP1 INHIBITORS, USES AND METHODS | LONP1, ACAT1, ACAA2 | CTSS 736/4885CTSL 1886/4885CTSB 584/4885 |
| US-20250059214-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, ACAT1, ACAA2 | CTSS 1040/4885CTSL 2674/4885CTSB 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.